Endocrine Board Review


CME and MOC may be claimed for CEU 2017 through October 31, 2018

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™ and ABIM Maintenance of Certification (MOC) points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss state-of-the-art research in endocrinology
  • Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
  • Employ enhanced skills and practice management techniques to improve patient care

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, internists, healthcare professionals who treat endocrine disorders, and others seeking an update in recent developments in the treatment of endocrine disorders.

Statement of Independence

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Clinical Endocrinology Update Steering Committee. The commercial supporters of this activity have no influence over the planning of this CME activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Amgen Inc.; Corcept Therapeutics Incorporated; Ethicon Endo-Surgery, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.; Radius Health, Inc.; Shire; and Versartis, Inc.*

*As of September 15, 2017